000266780 001__ 266780
000266780 005__ 20190627122413.0
000266780 022__ $$a1999-4915
000266780 0247_ $$a10.3390/v11040343$$2doi
000266780 02470 $$2isi$$a000467310600040
000266780 037__ $$aARTICLE
000266780 245__ $$aCurrent State of Compassionate Phage Therapy
000266780 260__ $$c2019-04-01
000266780 269__ $$a2019-04-01
000266780 336__ $$aReviews
000266780 520__ $$aThere is a current unmet medical need for the treatment of antibiotic-resistant infections, and in the absence of approved alternatives, some clinicians are turning to empirical ones, such as phage therapy, for compassionate treatment. Phage therapy is ideal for compassionate use due to its long-standing historical use and publications, apparent lack of adverse effects, and solid support by fundamental research. Increased media coverage and peer-reviewed articles have given rise to a more widespread familiarity with its therapeutic potential. However, compassionate phage therapy (cPT) remains limited to a small number of experimental treatment centers or associated with individual physicians and researchers. It is possible, with the creation of guidelines and a greater central coordination, that cPT could reach more of those in need, starting by increasing the availability of phages. Subsequent steps, particularly production and purification, are difficult to scale, and treatment paradigms stand highly variable between cases, or are frequently not reported. This article serves both to synopsize cPT publications to date and to discuss currently available phage sources for cPT. As the antibiotic resistance crisis continues to grow and the future of phage therapy clinical trials remains undetermined, cPT represents a possibility for bridging the gap between current treatment failures and future approved alternatives. Streamlining the process of cPT will help to ensure high quality, therapeutically-beneficial, and safe treatment.
000266780 542__ $$fCC BY
000266780 650__ $$aVirology
000266780 650__ $$aVirology
000266780 6531_ $$abacteriophage therapy
000266780 6531_ $$acompassionate use
000266780 6531_ $$aantibiotic resistance
000266780 6531_ $$apseudomonas-aeruginosa
000266780 6531_ $$abacteriophage therapy
000266780 6531_ $$asustained-release
000266780 6531_ $$aaccess
000266780 6531_ $$aprograms
000266780 6531_ $$adrugs
000266780 6531_ $$atrial
000266780 700__ $$g193965$$aMcCallin, Shawna
000266780 700__ $$aSacher, Jessica C.
000266780 700__ $$aZheng, Jan
000266780 700__ $$aChan, Benjamin K.
000266780 773__ $$q343$$k4$$j11$$tViruses-Basel
000266780 8564_ $$uhttps://infoscience.epfl.ch/record/266780/files/Current%20State%20of%20Compassionate%20Phage%20Therapy.pdf$$zFinal$$s606617
000266780 8560_ $$fbeatrice.marselli@epfl.ch
000266780 909CO $$ooai:infoscience.epfl.ch:266780$$particle$$preview
000266780 961__ $$abeatrice.marselli@epfl.ch
000266780 973__ $$rREVIEWED$$sPUBLISHED$$aEPFL
000266780 981__ $$aoverwrite
000266780 980__ $$aARTICLE
000266780 999C0 $$zJunod, Julien$$xU10127$$pSTAP$$mstephan.morgenthaler@epfl.ch$$0252209